Pharmaceuticals
Market Cap
₹103 ₹103 Cr.
P/E
13.90
PEG
0.80
PEG = P/E ÷ 5yr forward EPS CAGR
5yr forward EPS CAGR thesis · Base case

Thesis hinges on own-brand scale-up via wider B2B distribution and planned D2C expansion lifting its share of growth

Bull case requires faster own-brand conversion plus stronger third-party utilization; bear case is own-brand shortfall compounded by key-customer order cuts with no long-term contracts and single-facility dependence

Early confirmation comes from own-brand disclosure through FY28 alongside third-party run-rate and EBITDA margin discipline

  • Himalaya Nutravedics
  • Jeena Sikho Lifecare
  • Sandu Pharmaceutical

FAQs on Himalaya Nutravedics India Ltd. Shareprice

There is not enough historical data for the companies share price.

There is insufficient historical data to gauge this.
Latest PE of Himalaya Nutravedics is 14.61

Growth Table

  • Himalaya Nutravedics India Ltd.
  • Jeena Sikho Lifecare
  • Sandu Pharmaceutical

Balance Sheet

  • Himalaya Nutravedics India Ltd.
  • Jeena Sikho Lifecare
  • Sandu Pharmaceutical

Balance Sheet Snapshot

No data available.

Fund Flow Analysis

  • 1y
  • 3y
  • 5y
  • 10y
  • Increase
  • Decrease
  • Total
No data available.
*Data is as of latest FY end

Profit & Loss

  • Himalaya Nutravedics India Ltd.
  • Jeena Sikho Lifecare
  • Sandu Pharmaceutical

Cash Flow

  • Himalaya Nutravedics India Ltd.
  • Jeena Sikho Lifecare
  • Sandu Pharmaceutical

Cash Flow Analysis

  • 1y
  • 3y
  • 5y
  • 10y
  • Increase
  • Decrease
  • Total
No data available.

Ratios

= Dominant Factor
  • Himalaya Nutravedics India Ltd.
  • Jeena Sikho Lifecare
  • Sandu Pharmaceutical

Reverse DCF

locked
Cr
locked
5 YEAR
locked 5
10 YEAR
locked 10
20 YEAR
locked 20
Implied Growth Rate over a 5 year period*
Implied Growth Rate over a 10 year period*
Implied Growth Rate over a 20 year period*

FAQs on Himalaya Nutravedics India Ltd. Financials

Balance sheet of Himalaya Nutravedics is strong.
It shouldn't have solvency or liquidity issues.

Yes, The net debt of Himalaya Nutravedics is increasing.
Latest net debt of Himalaya Nutravedics is ₹2.26 Crs as of Mar-26.
This is greater than Mar-25 when it was ₹1.67 Crs.

Yes, profit is increasing.
The profit of Himalaya Nutravedics is ₹7.39 Crs for Mar 2026, ₹2.23 Crs for Mar 2025 and ₹0.43 Crs for Mar 2024

The company seems to be paying a very low dividend.
Investors need to see where the company is allocating its profits.
Himalaya Nutravedics latest dividend payout ratio is 0% and 3yr average dividend payout ratio is 0%

Companies resources are allocated to majorly unproductive assets like Inventory, Accounts Receivable

Ideas Dashboard
Results
Timeline
Watchlist
Portfolio
Alerts
Stock Screener
Market
Raw Material
Data feed provided by Accord Fintech